Dr. Trudy Vanhove is a seasoned biopharmaceutical executive and venture partner with nearly 30 years of experience leading drug development, regulatory strategy, and corporate growth across biotech and pharmaceutical companies. She has played a pivotal role in launching multiple FDA- and EMA-approved therapies and has a strong track record in building high-performing teams, driving strategic partnerships, and supporting financing efforts. Fluent in several languages and with extensive international experience, Dr. Vanhove brings a unique global perspective and a deep scientific and business acumen to board roles and investment opportunities in the biotech sector.

Eric Trac is a visionary healthcare investor and biopharmaceutical strategist with a unique blend of medical expertise and financial acumen, driving transformative growth in the healthcare sector. As a Senior Analyst & Director at Sarissa Capital Management, he leads activist investment strategies, evaluates public and private market opportunities, and serves as a board director at Lyndra Therapeutics. With a background in venture capital at Vida Ventures and Vivo Capital, he has played a pivotal role in high-impact transactions, including Bayer’s $4 billion acquisition of AskBio and Centessa Pharmaceuticals’ $250 million Series A. Trac’s deep scientific foundation stems from his MD and MBA from Stanford University and his research in biotechnology at MIT, where he graduated in the top 8% of his class. Recognized as one of *Business Insider’s* “14 Most Impressive Students at MIT,” he continues to leverage his expertise in medicine and finance to drive innovation, maximize shareholder value, and advance the future of biopharmaceuticals.